CoChat

Different responses to chronic somatostatin analogues in patients with central hyperthyroidism

Mannavola, Deborah, Persani, Luca, Vannucchi, Guia, Zanardelli, Maddalena, Fugazzola, Laura, Verga, Uberta, Facchetti, Marco, Beck‐Peccoz, Paolo · 2005 · Clinical Endocrinology
Cited by 104

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Objective Central hyperthyroidism is mainly due to two different causes, TSH‐secreting pituitary adenoma (TSH‐oma) and resistance to thyroid hormone in its pituitary variant, i.e. patients presenting with signs and symptoms of hyperthyroidism (PRTH). Because therapeutic approach and the clinical follow‐up are extremely different in these two disorders, a correct differential diagnosis is mandatory. Unfortunately, no definite pathognomonic tool is presently available and an extensive biochemical and instrumental workup is frequently needed in order to reach the correct diagnosis. Aim of the present study was to investigate the use of somatostatin analogues in the differential diagnosis between TSH‐omas and PRTH, as well as the possible treatment of PRTH with these analogues. Design and Patients Eight patients with TSH‐oma and four with PRTH underwent the acute test with somatostatin analogue Octreotide (0·1 mg subcutaneously), as well as long‐acting Octreotide‐LAR (30 mg intramuscularly every 28 days) for two months. Measurements Serum TSH, FT3 and FT4 were evaluated in basal condition, at time 0 and every hour for 6 h during acute test, and every 15 days for 2 months during chronic treatment. Results During acute test, in both patients with PRTH and TSH‐oma, a similar reduction in immunoreactive TSH and FT3 levels was observed, while no variations were found in FT4 concentrations. In contrast, during the administration of Octreotide‐LAR, no significant variations of all tested parameters were observed in PRTH group, whereas FT3 and FT4 concentrations normalized or presented a significant reduction (> 30% of pretreatment values) in seven of eight patients with TSH‐oma, despite minor variation of immunoreactive TSH levels. Conclusions Chronic administration of long‐acting somatostatin analogues in patients with central hyperthyroidism caused a marked decrease of FT3 and FT4 levels in all patients but one with TSH‐oma, while patients with PRTH did not respond at all. Thus, administration of long acting somatostatin analogues for at least 2 months can be useful in the differential diagnosis in problematic cases of central hyperthyroidism. Furthermore, the present findings exclude the possibility of a beneficial effect of chronic administration of somatostatin analogues in controlling thyrotoxic symptoms in PRTH patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2004.02192.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 104

Metadata

Authors
Mannavola, D., Persani, L., Vannucchi, G., Zanardelli, M., Fugazzola, L., Verga, U., Facchetti, M., & Beck‐Peccoz, P.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2004-12-23
Volume
62
Issue
2
Pages
176-181
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2084388049
Cited by
104
References
1
FWCI
1.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. https://app.cochat.ai/papers/10.1111/j.1365-2265.2004.02192.x
The paper
Mannavola, D., Persani, L., Vannucchi, G., Zanardelli, M., Fugazzola, L., Verga, U., Facchetti, M., & Beck‐Peccoz, P. (2005). Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2004.02192.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.